Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699314 | 1.00 | CFTR (0.56) | CFTRKDM4EHTTMAPK1LMNA | |
| SCHEMBL14783370 | 0.86 | CFTR (0.57) | CFTRKDM4EHTTNOTUM | |
| SCHEMBL16389694 | 0.84 | AGBL2 (0.50) | CFTRKDM4EMAPK1LMNAALDH1A1 | |
| SCHEMBL30481800 | 0.84 | AGBL2 (0.50) | CFTRKDM4EMAPK1LMNAALDH1A1 | |
| SCHEMBL16456041 | 0.84 | CFTR (0.53) | CFTRKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22208505 | 0.83 | MAPK1 (0.47) | CFTRKDM4EHTTMAPK1LMNA | |
| SCHEMBL15738696 | 0.82 | CFTR (0.57) | CFTRKDM4EHTTLMNAALDH1A1 | |
| SCHEMBL14783371 | 0.82 | CFTR (0.42) | CFTRKDM4EHTTMAPK1ALDH1A1 | |
| SCHEMBL31338969 | 0.81 | MAPK1 (0.59) | KDM4EHTTMAPK1LMNAALDH1A1 | |
| SCHEMBL4125681 | 0.81 | MAPK1 (0.59) | KDM4EHTTMAPK1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250320226-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | VERTEX PHARMA (US) | 2025-10-16 | — | — | US | disclosed |
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-06-05 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1732933-B1 | COMPOUNDS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1732933-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097805-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | CFTR 1105/4885KDM4E 2459/4885HTT 4277/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | CFTR 614/4885KDM4E 4515/4885HTT 2509/4885 |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, CLIC1 | CFTR 1/4885KDM4E 4300/4885HTT 3926/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | CFTR 591/4885KDM4E 4522/4885HTT 3218/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CFTR 1/4885KDM4E 1779/4885HTT 4068/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CFTR 810/4885KDM4E 1694/4885HTT 4504/4885 |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CFTR 1/4885KDM4E 4100/4885HTT 4308/4885 |
| US-20250320226-A1 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | CFTR, PKD1, AQP1 | CFTR 1/4885KDM4E 2916/4885HTT 3355/4885 |
| US-20070208003-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | PCSK9, LIPC, APOB | CFTR 1347/4885KDM4E 1101/4885HTT 3272/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | CFTR 1/4885KDM4E 4100/4885HTT 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.